ReviewNature reviews. Nephrology2011
Advances in human antiglomerular basement membrane disease.
Review in Nature reviews. Nephrology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 85 citations in OpenAlex.
- Article
- IgA nephropathy shortly follwed by seroconversion of positive anti-GBM antibodies and rapid progressive glomerulonephritis in a Chinese boy: coincidental overlap or pathogenic link?BMC nephrology · 2026Article
- Butyric Acid-Modified m-P14 Peptide Ameliorates Anti-Glomerular Basement Membrane Disease.International journal of molecular sciences · 2026Article
- Elevated serum soluble α3(IV)NC1 correlates with kidney injury and worse outcome in patients with anti-glomerular basement membrane disease.Frontiers in immunology · 2026Article
- The effect of frequent plasmapheresis in a patient with anti-glomerular basement membrane antibody diseases with severe renal dysfunction: a case report and literature review.Frontiers in immunology · 2026Review
- Perlecan is a novel target of autoantibodies in anti-glomerular basement membrane disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Article
- Serum matrix metalloproteinase-9 levels and enzymatic activity in patients with anti-glomerular basement membrane disease.Frontiers in medicine · 2025Article
- Bowman's capsule rupture and its clinical significance in patients with anti-glomerular basement membrane disease.Frontiers in immunology · 2025Article
- Complement in anti-glomerular basement membrane glomerulonephritis.Frontiers in immunology · 2025Review
- Case report: renal recovery in Goodpasture's syndrome treated with rituximab.Journal of nephrology · 2024Article
- Evaluation of the Risk Prediction Models in Predicting Kidney Outcomes in Antiglomerular Basement Membrane Disease.Kidney international reports · 2024Article
- Autoantibodies against laminin-521 are pathogenic in anti-glomerular basement membrane disease.Kidney international · 2023Article
- Clinical and immunological characteristics of patients with combined anti-glomerular basement membrane disease and IgA nephropathy.Clinical kidney journal · 2023Article
- Acute Ocular Complications after Recently Diagnosed Goodpasture's Syndrome - An Unusual Case of Hypertensive Retinopathy.Klinische Monatsblatter fur Augenheilkunde · 2023Article
- Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis.Archives of medical science : AMS · 2023Review
- Rituximab for the treatment of refractory anti-glomerular basement membrane disease.Renal failure · 2022Article
- Anti-glomerular basement membrane disease with IgA nephropathy: A case report.World journal of clinical cases · 2022Article
- The Th17 Pathway in Vascular Inflammation: Culprit or Consort?Frontiers in immunology · 2022Review
- Experimental Antiglomerular Basement Membrane GN Induced by a Peptide fromJournal of the American Society of Nephrology : JASN · 2020Article
- Anti-glomerular basement membrane nephritis with bronchial carcinoma: a case report.The Journal of international medical research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiglomerular basement membrane (anti-GBM) disease is an autoimmune disorder that mostly presents as raised titers of antibodies against the GBM, rapidly progressive glomerulonephritis and pulmonary hemorrhage. The disease is caused by antibodies against noncollagenous domain of α3 chain of type IV collagen, which contains the epitopes E(A) and E(B). The humoral and cellular immunity contributing to the initiation of anti-GBM disease has been extensively studied as a model for autoimmune diseases, although most of the data come from animal studies. The disease is rare, but diagnoses have been made in hundreds of patients. Substantial advances have been made in the understanding of human anti-GBM disease, and it can be treated successfully. In this Review we summarize the current knowledge on the prevalence, clinical manifestations, treatment and outcomes of human anti-GBM disease. We discuss findings on pathogenesis from human studies, with close attention to disease initiation and the immunological features of progression from quiescent autoimmune homeostasis in healthy individuals to fulminant anti-GBM disease. Further studies on autoreactive T cells are expected to clarify specific features of human anti-GBM disease and could lead to the development of new therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.